Antibody, Genetic Engineering, Protein and Vaccine

mRNA Cancer Vaccines and Therapies: An Overview

Advarra

JANUARY 11, 2024

While mRNA usage has played several roles in clinical research , oncology researchers in particular are eager to explore the possibilities of mRNA-based cancer vaccines. The mRNA constructs used in COVID-19 vaccines, for example, direct cells to produce a version of the “spike” protein studding the surface of SARS-CoV-2.

Vaccination

Vaccination Vaccine Protein Antibody

Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 VaccineAdvance purchase agreement signed for NVX-CoV2373, Novavax’ adjuvanted protein vaccine candidate

The Pharma Data

DECEMBER 16, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 million doses of NVX-CoV2373, Novavax’ candidate vaccine against COVID-19. About NVX-CoV2373.

Protein

Protein Vaccination Vaccine Immune Response

Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA

The Pharma Data

NOVEMBER 9, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate. Glenn, M.D., and globally.”. and globally.”.

Vaccination

Vaccination Vaccine Clinical Trials Clinical Trials

Novavax Announces COVID-19 Vaccine Clinical Development Progress

The Pharma Data

NOVEMBER 30, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. Vaccines Taskforce and National Institute for Health Research played pivotal roles in the rapid recruitment and enrollment of volunteers.

Clinical Development

Clinical Development Vaccination Vaccine Development

Advancements in upstream CLD for enhanced biotherapeutics production

Drug Discovery World

NOVEMBER 27, 2023

As the significance of large molecules continues to broaden across diverse modalities, emphasis on bispecific and multispecific antibodies to treat various disorders such as rheumatologic diseases, cancer, diabetes, anaemia, and infectious diseases becomes paramount. Biotechnol Bioeng 2012;118:2326. Budge JD, Knight TJ, Povey J, et al.

Production

Production Engineer Gene Editing Gene

Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform

XTalks

AUGUST 17, 2020

protein-based biologics) and vaccine treatments. This typically involves taking T cells from the body, engineering chimeric receptor antigens (CAR) and inserting them into the cells, expanding the cells ex vivo and injecting them back into the body. Treatment vaccines : these boost the immune system responses to target cells.

Protein

Protein Engineer Immune Response In-Vivo

Scottish drug discovery: advancing new research models

Drug Discovery World

MAY 25, 2023

Advances like genetically engineered mouse models (GEMMs), patient-derived xenografts (PDXs) and organoids are allowing the integration of mouse models with human cohorts. However, she has identified FFA4, a G protein-coupled receptor (GCPR) with the therapeutic potential to improve insulin sensitivity in metabolic disorders.

Research

Research Drugs In-Vitro Insulin

Clinical Catch-Up: January 4-8 | BioSpace

The Pharma Data

JANUARY 10, 2021

Arcturus Therapeutics got the FDA go-ahead for its Phase II trial of its COVID-19 vaccine candidate ARCT-021. CERC-002 is a human anti-LIGHT monoclonal antibody. China’s Sinovac Biotech reported that its COVID-19 vaccine, CoronaVac, had a 78% efficacy rate in a Phase III clinical trial in Brazil. Here’s a look.

Gene Therapy

Gene Therapy Trials Gene Clinical Trials

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody

Antibody Engineer Protein Scientist

Leading innovators in transcription factors for AAV for the pharmaceutical industry

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. There are two main genes in the AAV genome, rep and cap, which encode nine different proteins.

Gene

Gene Gene Therapy Genetics DNA

Biopharma Leaders Unite To Stand With Science

The Pharma Data

SEPTEMBER 8, 2020

Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US.

Vaccination

Vaccination Vaccine Containment Clinical Trials

Biopharma Leaders Unite To Stand With Science

The Pharma Data

SEPTEMBER 8, 2020

— Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US.

Vaccination

Vaccination Vaccine Containment Clinical Trials

How mice with humanised immune systems are advancing cell-based immunotherapy

Drug Discovery World

JULY 22, 2022

To mitigate these risks, clinicians are turning to other immunomodulators, such as cell-based therapies, bispecific antibodies, and cytokine treatments. NK and CAR-NK cells can mediate similar mechanisms of cytotoxicity through antibody-dependent cell cytotoxicity (ADCC) and act through the Fc? receptor 25.

In-Vivo

In-Vivo Engineer In-Vitro Antibody

Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease in PREVENT-19 Phase 3 trial

The Pharma Data

JUNE 25, 2021

Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% “Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines.

Vaccination

Vaccination Vaccine Trials Immune Response

Leading innovators in gene splicing using nucleases for the pharmaceutical industry

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Nucleases are enzymes that hydrolytically cleave the phosphodiester backbone of DNA.

Gene Splicing

Gene Splicing Gene Recombinant DNA Technology DNA

Elasmogen announces a panel of novel, potent, anti-COVID-19 therapeutic candidates identified through collaboration with U.S. research partners

The Pharma Data

JANUARY 24, 2021

At only one tenth the size of traditional antibodies new VNAR biologics could be used to both treat and protect against SARSCoV-2 infections. At Elasmogen we have been able to capture, using the latest protein and genetic engineering techniques, the immune system of 10,000 shark equivalents in a test-tube.

Antibody

Antibody Protein Research Genetic Engineering

After trial win, Novartis nabs COVID drug from Molecular Partners

pharmaphorum

JANUARY 10, 2022

The deal comes amid the first glimmers that COVID-19 may be starting to become less of an emergency – at least in countries with high vaccination coverage that seem to be handling the Omicron wave without their healthcare systems being overwhelmed.

Trials

Trials Drugs Antibody Genetic Engineering

RNA Therapeutics: A Novel Approach to Treating Diseases

Roots Analysis

OCTOBER 22, 2023

Coding RNAs include messenger RNA (mRNA) and short interfering RNA (siRNA), which encode proteins and silence gene expression, respectively. ASOs are short single-stranded nucleotides that bind to specific messenger RNAs and prevent the production of a particular protein.

RNA

RNA Protein Genetics Gene Expression

Clinical Research Informer

mRNA Cancer Vaccines and Therapies: An Overview

Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 VaccineAdvance purchase agreement signed for NVX-CoV2373, Novavax’ adjuvanted protein vaccine candidate

Trending Sources

Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA

Novavax Announces COVID-19 Vaccine Clinical Development Progress

Advancements in upstream CLD for enhanced biotherapeutics production

Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform

Scottish drug discovery: advancing new research models

Clinical Catch-Up: January 4-8 | BioSpace

What to expect from PEGS Europe 2023: Day 1

Leading innovators in transcription factors for AAV for the pharmaceutical industry

Biopharma Leaders Unite To Stand With Science

Biopharma Leaders Unite To Stand With Science

How mice with humanised immune systems are advancing cell-based immunotherapy

Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease in PREVENT-19 Phase 3 trial

Leading innovators in gene splicing using nucleases for the pharmaceutical industry

Elasmogen announces a panel of novel, potent, anti-COVID-19 therapeutic candidates identified through collaboration with U.S. research partners

After trial win, Novartis nabs COVID drug from Molecular Partners

RNA Therapeutics: A Novel Approach to Treating Diseases

Stay Connected